Development of novel immunotherapeutic approaches for the treatment of Epstein-Barr virus-associated malignancies. [ 2015 - 2017 ]

Research Grant

Researchers: Prof Scott Burrows (Principal investigator) ,  Prof David Price ,  Prof Rajiv Khanna

Brief description Epstein-Barr virus (EBV) is attributed to cause 200,000 cancer cases annually. Malignancies associated with EBV include nasopharyngeal carcinoma and Hodgkins lymphoma. These malignancies have been treated, with limited success, by “adoptive immunotherapy” in which the patients T cells are expanded in the laboratory by stimulation with this virus, and infused back into the patient. This project aims to assess three novel approaches to enhance this form of treatment for therapeutic consideration.

Funding Amount $AUD 378,940.38

Funding Scheme Project Grants

Notes Standard Project Grant